| Haley Thomason Mccollum, DC | |
|
101 W Washington St Ste C1, Ridgeland, MS 39157-2434 | |
| (601) 856-2383 | |
| (877) 294-2560 |
| Full Name | Haley Thomason Mccollum |
|---|---|
| Gender | Female |
| Speciality | Chiropractor |
| Location | 101 W Washington St Ste C1, Ridgeland, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164946398 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 1276 (Mississippi) | Primary |
| Provider Name | Olde Towne Chiropractic Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1447980198 PECOS PAC ID: 6103209028 Enrollment ID: O20220810000959 |
News Archive
At the Association for Glycogen Storage Disease's 41st Annual Conference, Dr. David Weinstein of UConn School of Medicine and Connecticut Children's presented his groundbreaking, one-year clinical trial results for the novel gene therapy treatment for glycogen storage disease.
Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.
In one of the first studies of the impact of publicly reporting quality measures on outpatient care, a research team has found that clinics made improvements in diabetes care when they began publicly reporting how they were treating patients with the chronic disease.
The study, which appeared in Health Affairs, focused on California and is thought to be the first of its kind to examine the impact of emergency department closures on the quality of patient care.
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Haley Thomason Mccollum, DC 101 W Washington St Ste C1, Ridgeland, MS 39157-2434 Ph: (601) 856-2383 | Haley Thomason Mccollum, DC 101 W Washington St Ste C1, Ridgeland, MS 39157-2434 Ph: (601) 856-2383 |
News Archive
At the Association for Glycogen Storage Disease's 41st Annual Conference, Dr. David Weinstein of UConn School of Medicine and Connecticut Children's presented his groundbreaking, one-year clinical trial results for the novel gene therapy treatment for glycogen storage disease.
Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.
In one of the first studies of the impact of publicly reporting quality measures on outpatient care, a research team has found that clinics made improvements in diabetes care when they began publicly reporting how they were treating patients with the chronic disease.
The study, which appeared in Health Affairs, focused on California and is thought to be the first of its kind to examine the impact of emergency department closures on the quality of patient care.
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
› Verified 6 days ago
Mr. William Brent Cumberland, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 6935 Old Canton Rd, Ste A, Ridgeland, MS 39157 Phone: 601-956-6050 Fax: 601-952-0738 | |
Dr. Gage Michael Rodriguez, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 101 W Washington St Ste C, Ridgeland, MS 39157 Phone: 601-856-2383 | |
Action Chiropractic Center Chiropractor Medicare: Medicare Enrolled Practice Location: 6935 Old Canton Rd, Ridgeland, MS 39157 Phone: 601-956-6050 | |
Family Chiropractic Chiropractor Medicare: Medicare Enrolled Practice Location: 575 Highway 51, Ridgeland, MS 39157 Phone: 601-605-4993 Fax: 601-707-9033 | |
Trevene Raven Cowan, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 6935 Old Canton Rd Ste A, Ridgeland, MS 39157 Phone: 601-956-6050 Fax: 601-952-0738 | |
Mr. Dominique Roch Chagnon, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 6935 Old Canton Rd, Ste A, Ridgeland, MS 39157 Phone: 601-956-6050 Fax: 601-952-0738 |